Overall, when the clinical stages of patients were analyzed (Table 1 and Table 2) in breast invasive carcinoma (BRCA), results indicated that the CDH1 DSC3, GJA1, ITGA6, ITGB6, LAMB3, KRT14, KRT16, KRT17, and KRT6B gene expression levels were significantly (p < 0.001) higher in stages 3 and 4 in all BRCA patients than in other clinical stages (Table 1). This evidence concerns the gene KRT16 and invasive breast carcinoma.